SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on May 2, 2016. The registrant is headquartered in Sydney, Australia, and files annual reports under Form 20-F. The filing serves to disclose specific corporate events rather than providing a comprehensive financial report for a fiscal period.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an informational report regarding intellectual property and does not contain financial statements or key performance indicators.
Material Changes
The primary material event disclosed in this filing is the grant of Japanese patents for the company's product candidate, IMP321, in the field of cancer treatment. No financial changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies. The sole focus is the regulatory milestone of securing patent protection in Japan.
Key Facts for Investor Verification
- The company received Japanese patent grants for IMP321 related to cancer applications.
- The filing is a Form 6-K dated May 2, 2016, signed by CEO Marc Voigt.
- No financial data or operational metrics are included in this specific report.
- Investors should refer to the company's Form 20-F for comprehensive financial and operational details.